Trial Profile
An Exploratory, Phase IIa Cross-Over Study to Demonstrate the Efficacy and Safety of A4250 in Patients with Primary Biliary Cirrhosis and Cholestatic Pruritus
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 03 Aug 2023
Price :
$35
*
At a glance
- Drugs Odevixibat (Primary)
- Indications Primary biliary cirrhosis; Pruritus
- Focus Adverse reactions; Therapeutic Use
- 27 Jul 2023 According to an Ipsen Media Release, The Committee for Orphan Medicinal Products (COMP), a scientific committee of the EMA, concurrently issued a negative opinion for the maintenance of Bylvays orphan drug designation in ALGS. This latter opinion prevents the retention of orphan-drug status in Bylvays marketing authorization in ALGS and might delay a final European Commission decision. Ipsen plans to submit an appeal in respect of the COMP opinion.
- 24 Oct 2017 Results presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 15 Oct 2016 Status changed from recruiting to discontinued.